FocalTherics™ Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
FocalTherics (Nasdaq: FOCL) reported second quarter 2026 continuing-operations (HIFU segment) revenue of $13.2 million, up 39% year-over-year, with U.S. Focal One procedure volume increasing 47%. The company sold 13 Focal One systems versus 9 a year ago and expanded its installed base to 184 systems worldwide.
Gross margin improved to 55.6% from 51.1%, while operating expenses rose to $15.4 million, including about $0.8 million of one-time rebranding and transition costs. FocalTherics posted an operating loss of $8.0 million and a net loss of $14.5 million (loss per share $0.39), influenced by a $5.5 million warrant valuation impact. Cash and equivalents were $21.5 million at June 30, 2026. The company reiterated 2026 HIFU revenue guidance of $50–54 million, implying 34–45% growth, completed its corporate name change, launched its first commercial Focal One endometriosis program in Europe, and announced a $40 million underwritten public offering expected to close August 14, 2026. ESWL and Distribution businesses are now classified as discontinued operations.
Positive
- Q2 2026 revenue $13.2 million, up 39% year-over-year
- U.S. Focal One procedures grew 47% year-over-year in Q2 2026
- Focal One system sales 13 units vs. 9 a year ago (44% growth)
- Gross margin improved to 55.6% from 51.1% year-over-year
- 2026 HIFU revenue guidance $50–54 million, implying 34–45% growth
- Cash and equivalents $21.5 million at June 30, 2026, up from $20.5 million year-end 2025
Negative
- Q2 2026 net loss $14.5 million vs. $6.4 million prior year
- Operating loss $8.0 million in Q2 2026 vs. $6.6 million in 2025
- Loss from warrant liability fair value change $5.5 million in Q2 2026
- Total shareholders’ equity negative $3.2 million vs. positive $19.4 million at year-end 2025
- Long-term debt $37.2 million vs. $15.9 million at December 31, 2025
- Operating cash outflow $6.7 million for first half 2026, though improved vs. $10.0 million in 2025
News Explained
At June 30, $37,197 thousand of long-term debt accompanied negative shareholders’ equity of $3,225 thousand.
The June 30 balance sheet reported total liabilities of
The balance sheet also listed
For the six months ended June 30, operating cash flow was
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 11 | Q2 preliminary earnings | Negative | -21.0% | Preliminary Q2 results, segment reclassification, and announced $40 million capital raise |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record showed a negative 24-hour reaction of -20.97% to preliminary Q2 2026 earnings despite reported revenue and gross-margin growth.
Key Terms
hifu medical
eswl medical
discontinued operations financial
asc 205-20 financial
bph medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FocalTherics™ Reports Second Quarter 2026 Financial Results
AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.
Second Quarter 2026 Results and Recent Highlights of Continuing Operations (HIFU Segment)
- Increased Revenue to
$13.2 million , a39% Increase Compared to the Prior Year Period - Delivered
47% U.S. Procedure Volume Growth over the Prior Year Period - Recorded 13 Focal One® Capital System Sales compared to 9 in the Prior Year Period, including 2 Conversions from Operating Leases
- Expanded Focal One System Installed Base to 184, including 96 in the U.S. and 88 Internationally
- Achieved
55.6% Gross Margin, Compared to51.1% in the Prior Year Period - Completed Corporate Name Change to FocalTherics™
- Launched First Commercial Focal One Endometriosis Program in Europe
- Announced Underwritten Public Offering for
$40 million of Gross Proceeds Expected to Close August 14, 2026
“We continue to demonstrate commercial success with our strongest second quarter ever, reflecting the growing strength of our core business and further supporting the strategic shift to Focal Therapy with our corporate rebranding to FocalTherics,” said Ryan Rhodes, CEO of FocalTherics. “Along with strong commercial momentum, we are also pleased with the developing progress of the endometriosis commercial launch in Europe and look forward to establishing additional Focal One programs to increase access to an important, non-surgical option for women with this highly debilitating condition. In addition, with expected proceeds from our ongoing capital raise, we will continue to accelerate commercial adoption in the global prostate cancer market while leveraging our multi-indication Focal One platform to grow market opportunities in treating endometriosis and expanding into benign prostatic hyperplasia or BPH. We will also continue to invest in our innovation and product development initiatives driving advances in AI-assisted treatments, FocalConnect™ telecollaboration technology, and integrating histotripsy together with HIFU on our Focal One platform.”
Second Quarter 2026 Financial Results for Continuing Operations (HIFU Segment)
Total revenue for the second quarter of 2026 was
Gross margin for the second quarter of 2026 was
Operating expenses were
Operating loss was
Cash and cash equivalents as of June 30, 2026 totaled
Reiterating 2026 Guidance for Continuing Operations (HIFU Segment)
- Total revenue of
$50.0 -$54.0 million , representing34% -45% year-over-year growth
Discontinued Operations
During the second quarter of 2026, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company’s operations and financial results. Accordingly, the Company’s unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company’s ESWL and Distribution operating segments as discontinued operations.
Prior-period results presented in this release have been recast to reflect this classification on a consistent basis. As a result, all continuing operations figures and growth rates presented herein reflect the Company's HIFU business only.
Conference Call Information
A conference call and webcast to discuss the second quarter 2026 financial results will be hosted by Ryan Rhodes, Chief Executive Officer and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.
| Date: | Thursday, August 13, 2026, at 4:30 p.m. Eastern Time |
| Domestic: | 1-800-245-3047 |
| International: | 1-203-518-9765 |
| Passcode: | FOCAL |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1767672&tp_key=2d69d92ca7 |
About FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved, and include statements such as quote from our Chief Executive Officer, the expected closing and proceeds from our offering, and our financial performance guidance. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.
Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Investor Contact
Louisa Smith
Gilmartin Group
investor.relations@focalone.com
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. Dollars, except per share data)
| Three Months Ended: | ||||
| June 30, | June 30, | |||
| 2026 | 2025 | |||
| $US | $US | |||
| Sales of goods | 9,527 | 6,385 | ||
| Sales of RPPs & leases | 2,758 | 2,155 | ||
| Sales of spare parts and services | 918 | 969 | ||
| TOTAL NET SALES | 13,203 | 9,509 | ||
| Other revenues | (0) | — | ||
| TOTAL REVENUES | 13,203 | 9,509 | ||
| Cost of sales | (5,865) | (4,646) | ||
| GROSS PROFIT | 7,338 | 4,863 | ||
| Research & development expenses | (2,317) | (2,291) | ||
| Selling, general & administrative expenses | (13,054) | (9,194) | ||
| Total operating expenses | (15,371) | (11,485) | ||
| LOSS FROM OPERATIONS | (8,033) | (6,623) | ||
| Interest (expense) income, net | (748) | (79) | ||
| Loss from change in fair value of warrant liability | (5,547) | | ||
| Currency exchange gains (loss), net | (76) | 362 | ||
| LOSS BEFORE TAXES FROM CONTINUING OPERATIONS | (14,404) | (6,340) | ||
| Income tax (expense) credit, net from continuing operations | (8) | (14) | ||
| LOSS FROM CONTINUING OPERATIONS | (14,412) | (6,354) | ||
| Income(loss) from discontinued operations, net of tax | (75) | (51) | ||
| NET LOSS | (14,487) | (6,406) | ||
| Loss per share – Basic and diluted | (0.39) | (0.17) | ||
| Average number of shares used in computation of EPS - basic and dilutive | 37,527,950 | 37,420,318 | ||
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. Dollars, except per share data)
| Six Months Ended: | ||||
| June 30, | June 30, | |||
| 2026 | 2025 | |||
| $US | $US | |||
| Sales of goods | 17,782 | 10,185 | ||
| Sales of RPPs & leases | 5,250 | 4,100 | ||
| Sales of spare parts and services | 1,764 | 1,724 | ||
| TOTAL REVENUES | 24,796 | 16,009 | ||
| Cost of sales | (11,496) | (7,989) | ||
| GROSS PROFIT | 13,300 | 8,020 | ||
| Research & development expenses | (4,784) | (4,648) | ||
| Selling, general & administrative expenses | (24,574) | (16,739) | ||
| Total operating expenses | (29,357) | (21,388) | ||
| LOSS FROM OPERATIONS | (16,057) | (13,368) | ||
| Interest (expense) income, net | (1,151) | (81) | ||
| Loss from change in fair value of warrant liability | (6,851) | — | ||
| Currency exchange gains (loss), net | 77 | (664) | ||
| LOSS BEFORE TAXES FROM CONTINUING OPERATIONS | (23,982) | (14,113) | ||
| Income tax (expense) credit, net from continuing operations | (25) | (23) | ||
| LOSS FROM CONTINUING OPERATIONS | (24,007) | (14,135) | ||
| Income(loss) from discontinued operations, net of tax | 437 | 285 | ||
| NET LOSS | (23,570) | (13,850) | ||
| Loss per share – Basic and diluted | (0.63) | (0.37) | ||
| Average number of shares used in computation of EPS - basic and dilutive | 37,481,986 | 37,406,202 | ||
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands of U.S. Dollars)
| June 30, | December 31, | |||
| 2026 | 2025 | |||
| $US | $US | |||
| Cash, cash equivalents | 21,542 | 20,452 | ||
| Accounts receivable, net | 10,060 | 14,948 | ||
| Inventory | 8,251 | 7,770 | ||
| Other current assets | 2,350 | 2,439 | ||
| Total current assets of discontinued operations | 16,812 | 11,555 | ||
| TOTAL CURRENT ASSETS | 59,015 | 57,164 | ||
| Property, plant and equipment, net | 8,635 | 8,789 | ||
| Goodwill | 735 | 757 | ||
| Other non-current assets | 6,164 | 6,181 | ||
| Total non-current assets of discontinued operations | - | 6,106 | ||
| TOTAL ASSETS | 74,548 | 78,997 | ||
| Accounts payable & other accrued liabilities | 17,830 | 17,436 | ||
| Deferred revenues, current portion | 6,395 | 6,452 | ||
| Short term borrowing | 1,860 | 4,386 | ||
| Other current liabilities | 1,786 | 3,005 | ||
| Total current liabilities of discontinued operations | 8,978 | 5,862 | ||
| TOTAL CURRENT LIABILITIES | 36,849 | 37,141 | ||
| Obligations under operating and finance leases non-current | 835 | 1,183 | ||
| Long-term debt, non-current | 37,197 | 15,903 | ||
| Deferred revenues, non-current | 923 | 768 | ||
| Other long-term liabilities | 1,970 | 1,632 | ||
| Total non-current liabilities of discontinued operations | - | 2,957 | ||
| TOTAL LIABILITIES | 77,773 | 59,584 | ||
| TOTAL SHAREHOLDERS’EQUITY | (3,225) | 19,413 | ||
| TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY | 74,548 | 78,997 |
EDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of U.S. Dollars)
| Six Months Ended | Six Months Ended | |||
| June 30, | June 30, | |||
| 2026 | 2025 | |||
| ($US) | ($US) | |||
| NET INCOME (LOSS) | (23,570) | (13,850) | ||
| Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) | 11,750 | 3,024 | ||
| OPERATING CASH FLOW | (11,820) | (10,827) | ||
| Increase/Decrease in operating assets and liabilities | 5,157 | 779 | ||
| NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES | (6,663) | (10,047) | ||
| Short term investments | — | — | ||
| Additions to capitalized assets produced by the company and other capital expenditures | (2,017) | (2,917) | ||
| NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES | (2,017) | (2,917) | ||
| NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES | 10,402 | (1,198) | ||
| NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | (632) | 2,231 | ||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 1,090 | (11,931) |
(1) including share-based compensation expenses for
EDAP TMS S.A.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
six months ended June 30, 2026
(Amounts in thousands of U.S. Dollars)
| Six months ended | HIFU | Reconciling | Total After | ||||||||
| June 30, 2026 | Division | Items | Consolidation | ||||||||
| Sales of goods | 17,782 | — | 17,782 | ||||||||
| Sales of RPPs & leases | 5,250 | — | 5,250 | ||||||||
| Sales of spare parts and services | 1,764 | — | 1,764 | ||||||||
| TOTAL REVENUES | 24,796 | — | 24,796 | ||||||||
| GROSS PROFIT (% of Net Sales) | 13,300 | 53.6 | % | — | 13,300 | 53.6 | % | ||||
| Research & development expenses | (4,784) | — | (4,784) | ||||||||
| Selling, general & administrative expenses | (20,309) | (4,265) | (24,574) | ||||||||
| OPERATING PROFIT (LOSS) | (11,792) | (4,265) | (16,057) |
